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Summary We report data on the transplantation of primary tumour cells and of lymph nodes containing
metastatic cells disseminated by a mammary carcinoma (LMCI) implanted s.c. in the Johns' Strain Wistar rat.
A new method is described for deriving the TD50 of metastatic cells and for comparing their lymphnodal
clonogenicity in the transplanted and the original, i.e. 'primary' tumour host. The TD50 for transplanted
primary LMC1 cells was -12 (fiducial limits 8-20 cells), and the latency of the 8-10mm tumours formed
(T8.-I) after inocula of 102 to 105 cells decreased linearly with the logarithmic increase in the number of cells
injected. From the T8-10 and tumour incidence data for transplanted inguinal, axillary and para-aortic nodes,
the TDSO for metastatic cells was calculated to be 1120 cells (fiducial limits 790-1603 cells) indicating that the
clonogenicity of naturally disseminated metastatic cells was about a 100 fold lower than that determined for
transplanted primary tumour cells. The incidence and T8-10 data for axillary, inguinal and para-aortic lymph
node metastases in primary-tumour-excised hosts suggests that, although metastatic cells may continue
translymphnodal dissemination in situ, their TD50 is still consistent with that determined by node
transplantation.
In contrast to the wealth of data on the cellular
transplantation of experimental tumours there are
few concerning the further seeding of cells that may
be released once tumour growth is established in
situ. In particular, the lack of an in vivo clonogenic
assay for spontaneous metastatic cells has limited
therapeutic studies of this aspect of the cancer
problem to the experimental use of clinical end-
points, e.g. prolonged survival or increased survival
rates (Van de Velde et al., 1977; De Ruiter et al.,
1982; Wondergem et al., 1985). In the 1950s
methods for assaying the clonogenicity and trans-
plantation kinetics of primary tumour cells were
developed (Hewitt, 1958; Berry & Andrews, 1961)
and this produced rapid progress in quantifying the
principal factors governing the clinical outcome of
primary tumour therapy (Steel, 1977). A similar
development in experimental tumour metastasis
could be just as important, e.g. in defining the basic
principles of adjuvant treatment of patients at
significant risk from occult metastases
(Salmon, 1977).
As indicated by Porter et al. (1973), a limiting
dilution (TD50) assay would be helpful in the study
of tumour metastasis but, presumably due to the
previous lack of a suitable animal model (Carr &
Carr, 1981; Fidler & Hart, 1982; Kim, 1984;
Vandenris et al., 1985) such an assay for metastatic
cells naturally disseminated by a transplanted
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tumour has not been reported. However, we have
been able to assess the numbers of metastatic cells
present in the inguinal and axillary lymph nodes of
rats after implantation of an isologous mammary
carcinoma LMC1 (Speakman & Dixon, 1980;
1981). More importantly the method adopted was
similar to a dilution assay but to avoid the need to
isolate metastatic cells from a node, their numbers
were assayed by determining the latency of the
tumour it formed after transplantation to a fresh
host. From the latency and incidence of tumour
positive nodes, it is also possible to derive a TD50
curve for metastatic cells and thus provide the basis
of an in situ cell survival assay after therapy
(Speakman, 1986). In this paper we present and
discuss our data on the lymphnodal clonogenicity
of untreated metastatic cells.
All the data were derived from only a few LMC1
generations using liquid-N2 stored material and no
changes in tumour transplantability or growth
characteristics were observed. Three types of
experiment were performed. The first to determine
the TD50 of LMC1 cells derived directly from the
primary tumour. The second involved the transfer
of axillary, inguinal and para-aortic lymph nodes
from tumour-bearing to fresh hosts to determine
from the incidence and latency of tumours formed
the TD50 of transplanted metastatic cells. In the
third, the subcutaneous primary tumour was
excised at various times after its implantation,
leaving the nodes to form overt metastases and thus
determine their incidence and latency in the
primary host.
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Materials and methods
Animals
Virgin female 180-200 g Johns' Strain Wistar rats,
produced by strict inbreeding within the laboratory
were used. They were allowed free access to food
and water, maintained in a 12h alternating
light/dark regime and kept in groups of five or six
throughout. Only aseptic surgical procedures were
used.
Tumour
LMC1 arose spontaneously in 1972 in an ex-
breeding female and was maintained initially by
serial s.c. transplantation until storage in liquid N2
at the 35th generation. By this stage the histological
differentiation of the tumour had been lost, but its
growth rate, and the median cycle time of its
clonogenic cells remained unchanged (Moore &
Dixon, 1977a). Prior i.p. injection of 200Gy
irradiated minced tumour tissue, or s.c. inoculation
with 106 irradiated tumour cells, does not influence
the cellular transplantability of the s.c. tumour
(Table I). In addition we have shown that axillary,
inguinal and para-aortic nodes metastases have the
same cellular kinetic and macroscopic growth rates
as the untreated primary tumour (Carter et al.,
1980; Dixon & Bagnall, 1985). It was not
established if the original or 1st to 35th generation
tumour metastasized, but this property was present
from 37th generation (Moore & Dixon, 1977b). In
this study only the 37-45th tumour generations
were used.
Cell transplantation assay
Suspensions of single tumour cells were prepared by
the sedimentation of minced primary tumour tissue
in PBS and syringing of the supernatant
(Speakman, 1986). These were sampled to count
microscopically intact trypan blue excluding cells
and then diluted to contain the required number
per 0.1 ml of inoculum. Four widely spaced
abdominal sites per rat were used, each receiving
the same s.c. inoculum. All sites, 8-80, depending
upon the number of cells per inoculum, were scored
for up to one hundred days to determine the
percentage developing tumours. These were
measured daily to determine when they attained a
mean diameter of 8-10mm (T8 10) and that they
subsequently exhibited the growth rate of the
LMC1. In some groups (Dixon & Bagnall, 1985;
Figures 2 & 3) where less than 103 cells were given
per site, rats developing either one, or two
(bilateral) tumours, had these excised at T8-10 to
allow for the possibility of tumours developing in
the remaining sites.
Lymph node transplanatation assay
Animals were implanted s.c. with a primary tumour
in their right posterior abdominal flank (Moore &
Dixon, 1977a), and randomized for killing 3 to 30
days later. At post-mortem, the ipse-lateral
inguinal, axillary and para-aortic nodes were trans-
planted immediately to a fresh host, using three of
the sites used for single cell assay. All rats were
then scored for up to 100 days to determine the
incidence, T8-,o and growth rate of the tumours
formed. In some groups where there was only a low
take-rate, individual tumours were excised at T8-10
to show that there was no inhibition of negative
sites. Also for other groups only the para-aortic
node was transplanted to check that a simultaneous
three node (i.e. inguinal, axillary and para-aortic) as
opposed to a single node transplant, was without
effect.
Lymph nodes in situ
Rats were implanted, randomized, and their
growing primary tumours excised (Dixon &
Speakman, 1979) up to 26 days later. After surgery,
all animals were scored for up to 100 days to
record the incidence of ipse-lateral inguinal, axillary
and para-aortic lymph node metastases. Although
metastases may also occur at other sites (Moore &
Dixon, 1979b; Dixon & Speakman, 1979), positive
inguinal, axillary and para-aortic nodes, develop
earlier and adrenal and iliac lymph node metastases
do not occur without seeding of the para-aortic
node (Dixon & Bagnall, 1986).
For rats excised at 13-26 days, all axillary and
inguinal lymph node metastases detected were
measured to determine their T8 10 relative to the
day the primary tumour was excised and to confirm
their growth was characteristic of LMC . Para-
aortic metastases could also be detected by
palpation and their growth measured, although
imprecisely, through the abdominal wall. However,
at post-mortem all animals were examined for para-
aortic metastases. These were removed to obtain
their mean diameter and the day on which they had
reached 8-10mm diameter was determined from the
growth curve for LMC1 (Dixon & Bagnall, 1985,
1986).
Results
Primary tumour cell assay
No tumours formed in any of 80 sites inoculated
with 3.3 x 10-2 cells, and all developed tumours if
given 104 cells or more. Between these limits, the
percentage of sites with tumours increased from 2.5
to 100% (Figure 1) and all data could be readilyCLONOGENICITY AND KINETICS OF METASTATIC CELLS
Table I Transplantability of primary tumour cells in naive and 'immunized' hosts
Latency of
Number of Number of Percent positive tumours
cells injected sites sites (±s.e.) (days + s.e.)
Naive 0.2 24 12.5+6.7 46
20 22 50.0+10.6 46+8
200 24 91.7+5.9 31+3
200,000 39 100 9+1
'Immunized' 0.2 24 16.7+7.6 44
20 47 40.4+7.2 42+4
200 52 86.5+4.7 30+4
200,000 25 100 9+ 3
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Figure 1 Transplantation of primary LMC, cells. All
data; mean +1 s.d.; one zero and six 100% datum
points outside the limits shown not plotted; curve
fitted as described in text; ---- computed TD,0 and
fiducial limits.
fitted by a single probit curve (Speakman, 1986).
The computed TD50, i.e. the 'cell dose' that
produced tumours in 50% of sites, was 12 (fiducial
limits 8-20 cells), and for all data the computed chi-
square was 11.96 with 13 degrees of freedom (df).
The T8-10 of tumours formed from inocula of
3 x 101 to 105 cells decreased linearly with the
logarithmic increase in the number of cells injected
(Figure 2). No further changes in T8-10 were
obtained for inocula containing less than 3 x 101 or
more than 105 cells. Analysis of all data for the
tumours produced (not shown) confirmed that their
growth was characteristic of LMC, and it was not
affected either by the presence of two or more
tumours in the same animal, or by the removal of
all but one tumour at T8-10.
Lymph node transplantation assay
The percentage of transplanted inguinal nodes
producing tumours increased directly with the time
they were left in the primary host (Figure 3a). In
contrast, axillary nodes, from the same host, only
produced tumours if they remained in situ for two
50
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Figure 2 The latency of LMC1 tumours formed by
s.c. transplantation of primary tumour cells. All data,
mean +1 s.d.: n=6-38, depending upon the percentage
takes.
weeks. Thereafter they produced tumours in fresh
hosts at the rate observed for inguinal nodes.
Consistent results were obtained for para-aortic
nodes irrespective of whether they were
transplanted singly or together with inguinal and
axillary nodes (Table II). These data were pooled
and showed that para-aortic nodes only produced
tumours if they were left in the primary host for 10
days or more. Between 10 and 18 days about 35%
of nodes were then found to be positive, but
thereafter the percentage of tumourous nodes
increased as for inguinal and axillary node
transplants (Figure 3a).
In general, the T8-10 of tumours formed by
transplanted nodes decreased the longer they were
left in the primary host (Table III), and thus their
latency was inversely correlated with the percentage
of tumours formed. This relationship would be
expected from the data for transplanted primary
cells (Figures 1 and 2), and detailed analysis showed
that it was the same relationship for inguinal,
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Figure 3 The percentage of nodes forming tumours in fresh and primary tumour-excised hosts.
(a) Transplanted nodes: * Inguinal, mean +1 s.d., n= 18 all data fitted by least squares; * Axilla, mean
+ 1 s.d., n = 18, 14-30 days fitted by least squares; A Aortic, combined data from single and three node assay,
mean +2 s.e., n = 36, 10-16 days free-hand fit, 19-30 days, least squares fit.
(b) In situ nodes: * Inguinal, * Axilla, Aortic, all data means + 1 s.d., n =24-28. Solid lines, least
squares fit of data, dashed lines, curves from corresponding transplanted nodes.
Table II Incidence of tumours formed
by transplantation ofpara-aortic nodes
Frequency oftakes
Day Pa with
transplanted Pa alone Ax+Ing
10 a 5/18
14 2/24 14/36
16 6/23 6/18
19 9/24 6/21
23 12/23 8/18
26 8/12 14/23
30 14/20 10/12
34 12/16 a
aNot assayed.
Table III Latencies of tumours formed by transplan-
tation of positive lymph nodes
T8_10 (days + s.e.)
Day
transplanted Inguinal Axilla Para-aortic
3 27 (1) a a
7 35 (4)
a a
10 30+5 (6) a 30+7 (5)
14 23+6 (26) 32+9 (9) 31+ 10 (16)
16 25+8 (7) 38±7 (6) 31+7 (11)
19 17+11 (16) 26+5(11) 27+8 (15)
23 18+6 (10) 19±6 (10) 23±7 (20)
26 16+7 (18) 23+8 (15) 22+7 (22)
30 16+7 (10) 13+4 (8) 18±7 (17)
34 b b 17+7 (12)
aNo positive nodes detected; bNot assayed.
Numbers in parentheses show number of measurable
positive nodes.
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axillary and para-aortic nodes. The T8-o data
(Table III) were therefore used to derive (from the
data shown in Figure 2) the mean number of
tumour cells present in positive nodes when
removed from the primary host, and then plotted as
a function either, of their time in the primary host
(Figure 4a), or the incidence of tumours formed by
transplantation of all (i.e. negative and positive)
nodes to fresh hosts (Figure 5).
Between 5 and 14 days in situ, the mean number
of metastatic cells in inguinal nodes increased from
about 102 to 2 x 103, but between 14 and 19 days
decreased to about 8 x 102 (Figure 4a). This
apparent loss of metastatic cells coincided with the
initial detection of about 102, and 2 x 102 tumour
cells in the axillary and para-aortic lymph nodes
respectively. After 19 days the mean number of
metastatic cells in the inguinal node again
increased, to about 2 x I04, but by then similar
numbers were present in the other nodes. For the
4 10_
._
0
10o3
o 102
0.
C)
0
0
co
40
(1 104 -
.0
cc 104
E0 c 103
10
Inguinal Aortic Axilla
a
5 10 1520253010 1520253035 10 15202530
Day lymph node assayed
Inguinal Aortic
AJ
Axilla
a
5 10 1520253010 1520253035 10 15202530
Day primary tumour excised
Figure 4 The mean numbers of metastatic LMC,
cells in positive lymph nodes.
(a) Assayed by node transplantation to fresh host at
times shown after primary tumour implantation. All
curves are a free-hand fit, means calculated from data
(Table III).
(b) Assayed in the primary tumour-excised host. All
curves are a free-hand fit, means calculated from data
(Table V).
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Figure 5 Data for metastatic cells spontaneously
disseminated to and then transplanted within intact
nodes removed from the primary tumour host. -
Inguinal,E* Axillary, A Aortic (single node), A Aortic
(with axillary and inguinal node), n=18-23 nodes
transplanted to obtain each datum point. Zero take
points not shown or used in computation of the fitted
curve ( ), the TD50 and its fiducial limits (I I).
The TD50 curve (-----) established for transplanted
primary tumour cells (Figure 1) is shown for
companison.
axillary node however, a transient loss of about
4 x 103 cells, may also have occurred between 23
and 26 days.
Despite differences in the time of first detection
and subsequent changes (Figure 3a), when the
number of malignant cells present (Figure 4a) was
plotted against the percentage of all nodes that
produced tumours on transplantation (Figure 3a)
all the data could be fitted (X2= 17.73, 17df, P=
0.406) with a common curve (Figure 5). Omitting
zero takes, for which no estimate of cell number
may be made, the computed TD50 was 1120 cells
(fiducial limits 791-1603 cells). Thus this analysis
indicates that metastatic cells in transplanted nodes
have a clonogenicity - 100-fold lower than for
primary tumour cells transplanted to the same sites.
This conclusion applies for each type of node
assayed, i.e. a single TD50 curve could be readily
fitted to the data for each node and the Z x2 for all
nodes was not significantly less than that for the
pooled data (Table IV).
In situ lymph node assay
Few rats developed nodal metastases within 3-12
days after excision of their primary tumours
(Figure 3b). Also there was no significant (P>0.10)
increase in the incidence of positive inguinal nodes
after 8-26 day excisions, and overall only 37+2.6%
(s.e.) developed metastases at this site. In contrast,
axillary metastases after 12-26 day excisions
increased at almost the same rate as tumours were
formed by transplanted nodes. The data for
metastasis to the para-aortic node were equivocal.
Although their incidence was dependent on the time
of surgery (0.02<P<0.05), the data were also1004 B. DIXON et al.
Table IV Computed parametersfor transplanted lymph nodes
95% Fiducial Degrees of Goodness
Lymph node TD50 limits X2 freedom offit (P)
Inguinal 890 449-1553 6.25 6 0.396
Axillary 1155 367-4928 3.10 5 0.684
Para-aortica 1170 678-2183 6.84 5 0.233
Para-aorticb 1541 772-4974 0.95 3 0.813
aPara-aortic node only transplanted; bPara-aortic node transplanted together
with inguinal and axillary node; x2 pooled-Ex2 =0.59, with 3df (P= 0.90).
Datum points for lymph nodes calculated to contain the same number of
cells but giving different percentage takes on transplantation were combined
for computer probit analysis. Thus the degrees of freedom were based on n-2
where n is the reduced number of datum points used to derive each TD50 and
its fiducial limits.
consistent (chi-square=0.885 with ldf) with the
results for transplanted nodes.
The latencies of metastases were only determined
during the later stages of the work (Dixon &
Bagnall, 1985; 1986) and by day 26 the size of the
primary tumour prevents its complete excision.
However there were sufficient data (Table V) to
compare with those obtained by node transplanta-
tion (Figures 4a and 5). The 'growth curves' for the
metastatic cells in situ were similar to those
determined by transplantation. The mean number
of metastatic cells present in inguinal and axillary
nodes between 13 and 19 days was however about
double that estimated by transplantation.
Conversely, over the same period fewer were
present after in situ assay of the para-aortic nodes
(Figure 4). Because of the greater errors in
determining the mean latency of metastases in situ
(Table V), these differences may not be significant.
Because metastases developed only in 20-60% of
animals (Figure 3b), and there was a limited range
Table V Latency of metastases in situ after primary
tumour excision
T8-10 (days +I s.d.)
Day I
excised Inguinal Axillary Para-aortic
13 22+6 (11) 33+12 (9) 35+15 (10)
14 20+6 (14) 29+6 (8) 34±8 (16)
16 20+5 (6) 21±7 (4) 33+10 (9)
19 24+10 (10) 23+8 (11) 34+9 (12)
23 22+9 (5) 20±8 (10) 28+7 (8)
26 17+6 (11) 18+8 (14) 16+7 (18)
24-28 animals assayed on each of the days shown.
Figures in parentheses show number of rats with
measurable metastases at stated site.
of latency data (Table V), no independent TD50
analysis was attempted. However comparison of the
data with the TD50 curves for transplanted primary
and metastatic cells was possible (Figure 6). The in
situ data were not compatible with the TD50 curve
for primary tumour cells, although widely scattered
they were better represented by the TD50 curve for
transplanted metastatic cells, suggesting that in the
primary host the TD50 for lymphnodal metastasis
may also be - 1000 cells.
Primarytumourcells Transplanted
.>100 - metastatic cells
u) 806- ,
CL U)60 ,//
4 20-1 1 0
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Calculated number of cells present in
positive nodes
Figure 6 In situ TD50 data for metastatic cells in the
lymph nodes in primary tumour-excised rats. S
Inguinal, * Axilla, * Aortic nodes. The number of
animals excised, and the incidence and latency of
metastases formed is given in Table V; TD50
curve for transplanted lymph nodes, ---- TD_O curve
for primary tumour cells.
Discussion
Lymphatic metastasis does not exclude haemato-
logical dissemination (Weiss, 1985), but the latter
plays no significant role in inguinal, axillary and
para-aortic lymph node metastasis of LMC1 and
is not considered further. For convenience ofCLONOGENICITY AND KINETICS OF METASTATIC CELLS 1005
presentation we discuss separately: the transplanta-
tion of primary tumour cells, the nodal trans-
plantation of metastatic cells, and because they are
clearly interdependent, the in situ seeding and trans-
lymphnodal passage of metastatic cells. Despite
their potential significance, these aspects of
spontaneous metastasis, aside from the work of
Hewitt and Blake (1975; 1977), have not been
studied previously using non-immunogenic tumours.
The transplantation ofprimary cells
With a TD50 of between 8 and 20, relatively few
primary tumour cells were required for the direct
transplantation of LMC1 subcutaneously and
nearly all sites developed tumours if inoculated with
35 cells or more (Figure 1). For those given less
than 35 cells, the mean latency of the tumours
formed remained constant at about 37 days
(Figure 2) and this presumably represents the
average time needed for sites seeded by one
clonogenic cell to produce a T8-10 tumour. For
inocula containing from 102 to 105 cells the data
indicate (Bruce et al., 1967) that cells in occult
subcutaneous LMC, tumours have a population
doubling time of about 2.5 days. This compares
with a doubling time of 2 days measured (Moore &
Dixon, 1977a) for T8 10 tumours formed by the
implantation of a pellet of minced LMC1 tissue
containing about 104 viable cells (Speakman, 1986).
This suggests that the growth curve of LMC1 may
be comparable before and after its subcutaneous
detection.
According to Figure 2, 1.4 x 106 cells should have
produced an 8-10mm diameter tumours im-
mediately. However the minimum T8 ,0, achieved
with 105 cells or more, was about 10 days
(Figure 2). This presumably reflects, firstly the limits
of subcutaneous and abdominal wall micro-
vasculature in meeting the initial requirements of
more than a few thousand cells and secondly, the
time required to meet this demand through neo-
vascularization (Folkman & Tyler, 1977) and the
provision of other stromal elements required for
sustained tumour growth (Falk, 1980). This minimal
latency corresponds, to within a day or so, to the
time required for implanted LMC1 tumour tissue to
vascularize (Speakman, 1986), initiate sustained
growth and produce a significant incidence of occult
metastases (Speakman & Dixon, 1981; Dixon &
Bagnall, 1985, 1986; and Figure 3b).
The transplantation ofmetastatic cells
Even when transferred within lymph nodes,
metastatic LMC1 cells still exhibited single cell
transplantation kinetics (Figure 5). Their reduced
clonogenicity may not, however, be attributed
simply to lymphnodal transplantation since the in
situ data were comparable with those for
transplanted metastatic cells (Figure 6). Also for
LMC1 tumour-specific immunity does not occur.
The tumour is isogeneic and pre-immunisation
either with viable tumour tissue which is then later
completely excised (Dixon & Bagnall, unpublished),
or with radiation sterilized LMC1 cells or tissue,
does not change its transplantability (Speakman,
1986, and Table I). Although non-immune host
response factors produced by a macroscopic
primary tumour may lead to 'metastatic inefficiency'
(Weiss, 1985), with LMC1 this should exert no
effect once nodes had been transplanted to fresh
hosts. Nevertheless this will need to be investigated
experimentally, e.g. by the disaggregation of positive
nodes and subcutaneous transplantation of the
metastatic cells released, and by the determination
of the latency of transplanted normal nodes after
their injection with known numbers of tumour cells.
However, with the CBA Carcinoma NT, which has
a relatively high TD50 of about 4000 cells, the
release of nodal metastatic cells reduced their
tumour forming capacity and conversely the incor-
poration of tumour cells within normal nodes,
increased their transplantability (Hewitt & Blake,
1977). Thus, if such effects occur with LMC1 the
transplantation of naturally disseminated metastatic
cells within intact nodes should have reduced rather
than increased their TD50. There are, however, two
other mechanisms that could have lead to the
differences observed, viz, tumour cell heterogeneity
(Fidler & Poste, 1982) or a Revesz Effect (Revesz,
1956).
Malignant cells within a tumour are known to be
heterogeneous in many respects (Owens et al., 1982)
and it may be argued that whereas experimental
disaggregation of a primary tumour selects for
highly clonogenic cells, the metastatic dissemination
of cells does not. With other tumours when highly
metastatic cell populations have been isolated, this
usually involves their in vitro passage (Weiss, 1985).
For LMC1 this does not provide unequivocal
evidence that spontaneous metastases must arise
from subpopulations of either high or low clono-
genicity. If natural selection for metastatic
properties does take place, for LMC1 this could
have already been completed during the sequential
transplantation history of the tumour. With LMC1,
metastases from the 37th and subsequent tumour
generations have the same microscopic DNA
content, cell-cycle and macroscopic growth
characteristics as primary tumour cells (Carter et
al., 1980; Dixon & Bagnall, 1985). Moreover,
subcutaneous tumours produced by the transfer of
LMC1 positive lymph nodes, metastasize no more
frequently than tumours produced by the direct
passage of the primary tumour. In addition the
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sequential passage of LMC1 by the transplantation
of tumour positive lymph nodes still does not
enhance metastasis (Dixon & Bagnall, unpublished).
The TD50 of many tumours may be reduced by a
factor of 102 or more by adding an excess of
radiation sterilized cells to the viable inoculum to
stimulate the formation of fibrin at the site of assay
(Revesz, 1956, 1958; Peters & Hewitt, 1974; Steel,
1977). However, for LMC1 a Revesz Effect could
only reduce the TD50 of primary tumour cells 8- to
20-fold and their clonogenicity may already be fully
enhanced by the non-clonogens and angiogenesis
factors present within inocula prepared directly
from the macroscopic tumour (Folkman & Tyler,
1977). In contrast, the natural dissemination,
trapping and nodal transplantation of occult
metastatic LMC1 cells requires no direct, i.e.
cellular manipulation, and insufficient to have
stimulated angiogenesis (Figure 4) within the node
were involved. Also lymphoid cells are unable to
produce a Revesz Effect (Hewitt et al., 1973; Steel,
1977) and metastatic cells contained within the
node may not be exposed to fibrin stimulated to
form by node transplantation. Although also
requiring further investigation, these contrasting
circumstances could readily account for the 100-
fold difference in the TD50 of transplanted primary
tumour and metastatic LMC1 cells. Irrespective of
the mechanism, however, a clonogenic assay is only
valid if the method used has no influence on the
clonogenicity of tumour cells and this is not true of
LMC1. On this basis therapeutic studies of tumour
'metastases' initiated by the intravenous or intra-
lymphatic injection of primary tumour cells may
over-estimate their clonogenicity and the therapy
required to ablate spontaneous metastatic foci.
The seeding and lymphnodal kinetics of metastatic
cells
Although the in situ data conform approximately to
the TD50 curve derived for transplanted metastatic
cells, their poor fit (Figure 6) indicates that factors
additional to clonogenicity may be involved in
nodal metastasis in the primary host. About one
third of cells spontaneously disseminated by a
transplanted tumour may be micro-emboli of 2-8
cells or more (Liotta et al., 1976). However, emboli
of 2, 3, or 4 clonogenic cells etc., would have
progressively smaller TD50s and steeper trans-
plantation curves than single cells. Alternatively, if
each clonogenic cell was surrounded by non-
clonogens, this may change the TD50 but not the
steepness of the curve. Neither of these mechanisms
therefore provides a ready explanation of the in situ
data which although widely scattered suggests a
clonogenicity comparable with transplanted
metastatic cel(s.
Variability in the TD50 data would occur if
nodes differed in their ability to trap and initiate
the growth of metastatic cells or if they continued
to spread through the lymphatics after excision of
the primary. No significant variability was observed
for each of the nodes when assayed by trans-
plantation and the TD50 for each was about the
same (Table IV). However, whilst transplantation
'traps' metastatic cells within nodes they may
continue dissemination, although possibly at a
modified rate in the excised host. If this is the
factor modifying the in situ data it is amenable to
assay, e.g. by the use of the lymph node transplants
at various times after primary tumour excision.
However we have already shown that whereas
inguinal and axillary nodes are seeded by the
primary tumour, para-aortic nodes are seeded
largely by cells from already positive nodes (Dixon
& Bagnall, 1986). It is presumably this same
mechanism that delays the increased frequency of
tumour formation by transplanted para-aortic
nodes (Figure 3a), and is expressed in cellular terms
when latency is used to derive the numbers of
metastatic cells they contain (Figure 4).
For LMC1, about 100 cells are required to
produce positive inguinal nodes (Figure 4a). When
these are left in situ for a further 7 days their
metastatic cell content is increased with an effective
population doubling time of about 2 days, i.e.
similar to that determined for subcutaneously
injected single cells. When the metastatic cell
content in the inguinal node reaches about 2 x 103
cells, i.e. a tumour cell population at least a 100-
fold smaller than that required to demonstrate
physiological inhibition in the development of
tumours produced by single cell inocula (Figure 2),
there is a transient loss of cells. Since no
comparable loss is indicated for axillary and para-
aortic nodes transplanted with this number of cells
(Figure 4a), and it also occurs for inguinal nodes
left in the primary host (Figure 4b) it is most
unlikely to be an artefact. Qualitatively similar
changes in the number of metastatic cells passing
through the prepopliteal nodes draining the footpad
of rats given 2 x 107 Walker carcinoma cells 6 days
previously has also been reported (Carr & Carr,
1981).
Hewitt and Blake (1975) have also shown, using
the isogeneic WHT carcinoma, that the translymph-
nodal passage of spontaneously disseminated cells
may occur. With their intradermal tumour, about
40% of axillary nodes were positive on assay in
fresh hosts, irrespective of their time of removal
from the primary host. However, only about 4% of
primary tumour-excised hosts developed axillary
metastases and they concluded that disseminated
tumour cells mostly only pass through the node to
the blood, to be destroyed. Later Hewitt and BlakeCLONOGENICITY AND KINETICS OF METASTATIC CELLS 1007
(1977) supported this conclusion with data for four
other tumours but in each case only did one
comparative transplantation/in situ assay. Our data
for LMC1 shows, however, that their conclusion
may not be applied indiscriminately to all tumours
and indeed to all lymphatic nodes draining the
same tumour.
For LMC1 no significant loss of metastatic cells
occurs from the axillary node, i.e. the incidence of
positive nodes was the same in situ and after
transplantation, and once initiated the incidence of
metastases was directly dependent on the duration
of lymphatic drainage of the primary tumour
(Figures 3a, b). In contrast, comparison of the two
sets of data for the inguinal node clearly indicate
an early and later a substantial loss of metastatic
cells from the node when left in situ after excision
of the primary tumour. Although equivocal,
comparison of the in situ and transplant data for
the para-aortic node (Figures 3c, 4), indicates that
after its inital seeding and the passage through it of
inguinal node-disseminated tumour cells, no further
significant loss of metastatic cells may occur. From
these data it may also be concluded that, unlike the
WHT carcinoma, the LMC1 tumour has a high
overall rate of initiating lymphatic metastases in
situ, and that the translymphnodal passage of
tumour cells when it occurs has a high probability
of seeding metastases elsewhere, e.g. in the
mediastinum (Dixon & Bagnall, 1985, 1986).
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